Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda)
Esophageal Squamous Cell Carcinoma
Explore 64 assets in Esophageal Squamous Cell Carcinoma →Floatz Rating
C33/100
Confidence
Indicative
Sponsor
Sanofi
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
18Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05104567CT.gov A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) (this asset) | Sanofi | P2 | C · 33 |
| Fluorouracilum | AstraZeneca | P3 | BB |
| Levofolinic Acid | Taiho Oncology, Inc. | P3 | BB |
| Irinotecan | Taiho Oncology, Inc. | P2 | BB |
| Oxaliplatin | Taiho Oncology, Inc. | P3 | B |
| Cetuximab | Hummingbird Bioscience | P2 | B |
| Pembrolizumab | GV20 Therapeutics | P3 | B |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P3 | B |
| Capecitabine | Chongqing University Cancer Hospital | P2 | B |
+42 more in the Esophageal Squamous Cell Carcinoma cohort
Other indications for Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P2 | C · 33 |
| Hepatocellular Carcinoma | — | P2 | C · 33 |
| Colorectal Cancer | — | P2 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) in Esophageal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-interleukin-2-il2-t-cell-growth-factor-tcgf-2-133-variant-a1-deleted-pro65lys-cys125ser-non-glycosylated-produced-in-escherichia-coli-conjugated-at-n6-of-k65-with-a-peg-derivative-30kda-esophageal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →